SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Allora is a decentralized intelligence network that makes artificial intelligence more adaptive, collaborative, and efficient. The platform combines and coordinates thousands of specialized AI models in real time to produce superior inferences for users and applications. By enabling anyone to contribute models, data, or validation, Allora creates a self-improving market for intelligence that powers agents, DeFi systems, and AI applications across chains.

Allora

Allora is capturing trader attention due to its position in the AI-optimization sector, with bullish participants betting on sustained momentum and potential technical breakouts. While some community members view the price volatility as a sign of a pump-and-dump scheme, others highlight the project's limited circulating supply and incoming project updates as key catalysts for growth.

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Unicycive Therapeutics is trending as investors weigh the company's path toward NDA resubmission following a manufacturing-related delay, with community sentiment split between frustration over share dilution and confidence in the long-term potential of its OLC drug candidate. The core discussion remains focused on the upcoming regulatory updates, the company's cash runway, and whether management can regain credibility through a successful Type A meeting with the FDA.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF is experiencing significant volatility driven by massive spikes in put option interest as investors hedge against a potential market correction following a sharp single-session drop. While the community is debating whether this signals an AI-driven bubble ready to burst or a dip-buying opportunity, the broader discourse remains focused on the critical role of South Korean semiconductor giants like Samsung and SK Hynix in sustaining the global AI infrastructure cycle.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

The KORU ETF is attracting intense community attention as traders debate the sustainability of its parabolic rally, which is largely driven by South Korea's dominant memory chip manufacturers and significant volatility inherent in a 3x leveraged fund. While some participants are aggressively scaling into positions to capitalize on structural AI memory demand, others warn of significant downside risk from rapid leverage decay and the potential for a sharp correction in the broader Korean market.

Chip

CHIP is seeing significant community debate as bulls highlight its role in financing the AI compute infrastructure sector, while bears criticize persistent price declines and concerns over token supply. Traders are actively speculating on the potential for a short squeeze driven by the token's high volume and volatility, as market participants weigh the project's utility against ongoing sell pressure.

ViaSat, Inc. engages in providing communications technologies and services. It operates through the Communication Services and Defense and Advanced Technologies business segments. The Communication Services business segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets. The Defense and Advanced Technologies business segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging the company’s technical competencies in encryption, cyber security, tactical gateways, modems, and waveforms. The company was founded by Mark D. Dankberg and Mark J. Miller on May 1, 1986 and is headquartered in Carlsbad, CA.

Viasat, Inc.

Viasat is trending as the market weighs the company's potential split of its defense business against broader sector volatility, with community debate centered on whether to trade the tactical volatility or hold for long-term structural execution. While some participants are wary of its heavy debt load and competition, the stock remains a focal point due to its expanding government and military contract footprint and recent speculative interest regarding portfolio strategic reviews.

Onto Innovation, Inc. engages in the business of designing, development, manufacturing, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. It is also involved in providing process and yield management solutions used in bare silicon wafer production and wafer processing facilities. The company was founded in 1940 and is headquartered in Wilmington, MA.

Onto Innovation Inc.

Onto Innovation is gaining significant traction within the semiconductor sector as investors monitor its critical role in advanced packaging and metrology for AI-driven chip architectures. The community is actively discussing the stock's resilient technical structure and its strategic positioning in the evolving high-bandwidth memory (HBM) supply chain, with many highlighting potential upside driven by long-term data center expansion.

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK Plc - ADR

Glaxosmithkline plc - ADR

GlaxoSmithKline (GSK) is capturing community attention as investors anticipate a potential asset sale or strategic move involving Spero Therapeutics (SPRO) to capitalize on the upcoming tebipenem HBr FDA decision. Discussions are heavily focused on the high likelihood of a corporate metamorphosis for SPRO through a potential reverse merger or deal that would clear GSK's royalty obligations while expanding their oncology footprint in the Boston biotech corridor.

Eaton Corp. Plc is a power management company, which provides energy-efficient solutions for electrical, hydraulic, and mechanical power. It operates through the following segments: Electrical Americas and Electrical Global; Aerospace, Vehicle, and eMobility. The Electrical Americas and Electrical Global segments engage in sales contracts for electrical components, industrial components, power distribution and assemblies, residential products, single and three phase power quality, wiring devices, circuit protection, utility power distribution, power reliability equipment, and service. The Aerospace segment supplies aerospace fuel, hydraulics, and pneumatic systems for commercial and military use. The Vehicle segment deals with the design, manufacture, marketing, and supply of drivetrain and powertrain systems and critical components that reduce emissions and improve fuel economy, stability, performance and safety of cars, light trucks and commercial vehicles. The eMobility segment designs, manufactures, markets, and supplies electrical and electronic components and systems that improve the power management and performance of both on-road and off-road vehicles. The company was founded in 1911 and is headquartered in Dublin, Ireland.

Eaton Corporation plc

Eaton Corporation is trending as investors focus on its critical role in providing electrical infrastructure for the AI data center supercycle, with the community highlighting its massive backlog and role in solving power and thermal bottlenecks. Discussion is currently fueled by speculative institutional trading activity and the company's strategic positioning within the broader electrification and grid modernization theme.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is gaining investor attention behind strong Q1 sales growth from INGREZZA and the launch of CRENESSITY, alongside active discussions regarding a rare-disease acquisition strategy. The community remains focused on the company's solid fundamentals and ongoing pipeline execution as it attempts to break through recent technical resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by Guggenheim

Guggenheim upgraded Corbus Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday...

Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday

Corbus Pharmaceuticals (NASDAQ:CRBP) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-corbus-pharmaceuticals-holdings-inc-stock...

Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Crosses Above Fifty Day Moving Average   - Should You Sell?

Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Above 50-Day Moving Average - Should You Sell...

Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by Wall Street Zen to "Sell" Rating

Wall Street Zen raised shares of Corbus Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the...

Corbus Pharmaceuticals Holdings, Inc. $CRBP Stock Holdings Lifted by Aberdeen Group plc

Aberdeen Group plc lifted its position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 602.2% during the 4th quarter, according to the company in its most recent disclosure...

Corbus Pharma Aligns With FDA On Registration Path For CRB-701 In HNSCC And Cervical Cancer

(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical-stage company, Tuesday announced that it broadly aligned with the FDA on the registration path for CRB-701, a highly stable Nectin-4 targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical c...

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving Average - Time to Sell?

Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Pass Above 50 Day Moving Average - What's Next...

HC Wainwright Issues Negative Forecast for CRBP Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at HC Wainwright dropped their Q1 2026 earnings estimates for shares of Corbus Pharmaceuticals in a research...

How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%

The mean of analysts' price targets for Corbus Pharmaceuticals (CRBP) points to a 318.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Current Price	$7.56
Prev Close	$8.01
Open	$7.91
Dividend Yield	0.00%
50-Day Moving Average	$9.82
Beta	1.23
Avg. Volume	664,179.03
PE Ratio	-1.30

52-Week High	$20.56
52-Week Low	$6.72
Market Capitalization	$140.07M
EPS (Annual)	-$5.90
Price to Book	1.06
Revenue Per Employee	$0.00

CRBPCorbus Pharmaceuticals Holdings Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRBP News